Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 3
Abstract
Precision medicine promises to improve both the efficacy and safety of therapeutic products by better informing why some patients respond well to a drug, and some experience adverse reactions, while others do not. Pharmacogenomics is a key component of precision medicine and can be utilized to select optimal doses for patients, more precisely identify individuals who will respond to a treatment and avoid serious drug-related toxicities. Since pharmacogenomic biomarker information can help inform drug dosing, efficacy, and safety, pharmacogenomic data are critically reviewed by FDA staff to ensure effective use of pharmacogenomic strategies in drug development and appropriate incorporation into product labels. Pharmacogenomic information may be provided in drug or biological product labeling to inform health care providers about the impact of genotype on response to a drug through description of relevant genomic markers, functional effects of genomic variants, dosing recommendations based on genotype, and other applicable genomic information. The format and content of labeling for biologic drugs will generally follow that of small molecule drugs; however, there are notable differences in pharmacogenomic information that might be considered useful for biologic drugs in comparison to small molecule drugs. Furthermore, the rapid entry of biologic drugs for treatment of rare genetic diseases and molecularly defined subsets of common diseases will likely lead to increased use of pharmacogenomic information in biologic drug labels in the near future. In this review, we outline the general principles of therapeutic product labeling and discuss the utilization of pharmacogenomic information in biologic drug labels.
Authors and Affiliations
Robert N. Schuck, Joseph A. Grillo
Keywords
Related Articles
- EP ID EP680866
- DOI 10.1208/s12248-016-9891-4
- Views 54
- Downloads 0
The Role of Megalin in the Transport of Gentamicin Across BeWo Cells, an In Vitro Model of the Human Placenta
Aminoglycosides (AG) are known to readily cross the placenta, although the mechanisms responsible for placental transport have not been characterized. Megalin is expressed in human placenta, and it is reasonable to specu...
Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics
Drug transporter expression in tissues (in vivo) usually differs from that in cell lines used to measure transporter activity (in vitro). Therefore, quantification of transporter expression in tissues and cell lines is i...
AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology
The first International Symposium of Nanomedicine on AIDS “AIDS Treatment with Novel Anti-HIV compounds Improved by Nanotechnology” was held November 19–20, 2009 in Beijing, China. This symposium...
Targeted lipidomics: Discovery of new fatty acyl amides
The discovery of endogenous fatty acyl amides such asN-arachidonoyl ethanolamide (anandamide),N-oleoyl ethanolamide (OEA), andN-arachidonoyl dopamine (NADA) as important signaling molecules in the central and peripheral...
Pulmonary Immunization of Guinea Pigs with Diphtheria CRM-197 Antigen as Nanoparticle Aggregate Dry Powders Enhance Local and Systemic Immune Responses
This study establishes the immune response elicited in guinea pigs after pulmonary and parenteral immunizations with diphtheria CRM-197 antigen (CrmAg). Several spray-dried powders of formalin-treated/untreated CrmAg nan...